Multiple Myeloma: Belantamab Mafodotin plus Pomalidomide and Dexamethasone Show Significant Higher PFS, Deep Response and OS vs Those of Standard of Care

At the late-breaking oral session professor Meletios Dimopoulos presented the results from the randomized phase 3 DREAMM-8 study of the efficacy and safety of belantamab mafodotin plus pomalidomide and dexamethasone vs those of standard of care pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with lenalidomide.